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DObjectives: The scientific understanding of aortic dilation associated with bicuspid aortic valve (BAV) has
evolved during the past 2 decades, along with improvements in diagnostic technology and surgical management.
We aimed to evaluate secular trends and predictors of thoracic aortic surgery among patients with BAV in the
United States.
Methods:We used the 1998-2009 Nationwide Inpatient Sample, an administrative dataset representative of US
hospital admissions, to identify hospitalizations for adults aged 18 years or more with BAVand aortic valve or
thoracic aortic surgery. Covariates included age, gender, year, aortic dissection, endocarditis, thoracic aortic
aneurysm, number of comorbidities, hospital teaching status and region, primary insurance, and concomitant
coronary artery bypass surgery.
Results: Between 1998 and 2009, 48,736  3555 patients with BAV underwent aortic valve repair or replace-
ment and 1679  120 patients with BAVunderwent isolated thoracic aortic surgery. The overall number of sur-
geries increased more than 3-fold, from 4556  571 in 1998/1999 to 14,960  2107 in 2008/2009 (P<.0001).
The proportion of aortic valve repair or replacement including concomitant thoracic aortic surgery increased
from 12.8%  1.4% in 1998/1999 to 28.5%  1.6% in 2008/2009, which mirrored an increasing proportion
of patients with a diagnosis of thoracic aortic aneurysm. Mortality was equivalent for patients undergoing aortic
valve repair or replacement with thoracic aortic surgery and those undergoing isolated aortic valve repair or re-
placement (1.8% 0.3% vs 1.5% 0.2%; multivariable odds ratio, 1.02; 95% confidence interval, 0.67-1.57),
with decreasing mortality over the study period (from 2.5%  0.6% in 1998/1999 to 1.5%  0.2% in 2008/
2009; multivariable odds ratio per 2-year increment, 0.89; 95% confidence interval, 0.81-0.99; P ¼ .03). Total
charges for BAV surgical hospitalizations increased more than 7.5-fold from approximately $156 million in
1998 to $1.2 billion in 2009 (inflation-adjusted 2009 dollars).
Conclusions: There was a marked increase in the use of thoracic aortic surgery among patients with BAV.
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The Journal of Thoracic and Cawell as thoracic aortic dilation and dissection. Aortic
dilation was long considered to be due to valve disease
itself, but increasing evidence points to an independent
aortopathy associated with BAV.3-6 Although the relative
risk of aortic dissection is lower than in Marfan syndrome,
there are likely as many, if not more, dissections in
patients with BAV given the significantly greater
prevalence of this disease.7 Therefore, BAV-associated aor-
tic disease has important public health implications.
Surgical management of aortic dilation and aneurysm
presents a difficult clinical problem given the unpredictable
lifetime risk of morbidity and mortality7-9 related to BAV
aortopathy and major surgical intervention required to
address these risks. This is not a new clinical issue; the
complexities of aortic aneurysmal disease have long been
appreciated,10,11 but our understanding and ability to
diagnose and intervene have evolved considerably.
Recommendations on when to intervene surgically for
thoracic aortic dilation, in general and for patients with
BAV, have been progressively expanded over the past 15rdiovascular Surgery c Volume 146, Number 2 339
Abbreviations and Acronyms
ACC ¼ American College of Cardiology
AHA ¼ American Heart Association
AVR ¼ aortic valve repair or replacement
BAV ¼ bicuspid aortic valve
CI ¼ confidence interval
OR ¼ odds ratio
TAA ¼ thoracic aortic aneurysm
TAS ¼ thoracic aortic surgery
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Dyears. Indeed, BAV is now widely considered to be an
independent risk factor for an acute aortic event, leading
to a lower threshold for aortic surgery in patients with
BAV compared with ‘‘degenerative’’ thoracic aortic
aneurysms (TAAs).12 Bicuspid aortopathy is increasingly
thought of as a genetic disease affecting aortic structure
and metabolism, with some arguing that aortic dimensions
indicating surgical intervention should be similar to those
used for other such genetic diagnoses, such as Marfan syn-
drome.13-15 Absolute aortic diameter remains the most used
clinical parameter to guide intervention, although indexed
and nonsize predictors also have been proposed.16-18
Guideline recommendations for surgical intervention
based on a threshold of ascending aortic diameter have
decreased from more than 5 cm19-22 to more than 4.5 cm
for patients with BAV undergoing concomitant aortic
valve repair or replacement (AVR), with others proposing
even lower thresholds for intervention.16,23,24 However,
these recommendations remain controversial.9,25,26
This study aims to elucidate practice patterns in the sur-
gical management of the thoracic aorta in patients with
BAV by examination of a representative dataset of US hos-
pitalizations over a recent 12-year period.MATERIALS AND METHODS
We used the 1998-2009 Nationwide Inpatient Sample (Healthcare Cost
and Utilization Project, Agency for Healthcare Research and Quality), the
largest all-payer nationally representative hospital discharge database in
the United States, to investigate the epidemiology of AVR and thoracic aor-
tic surgery (TAS) among adults (aged 18 years) with BAV. This database
has been used to study other aspects of hospitalizations for congenital heart
disease and noncongenital cardiac surgery.27-30 Because this study used
publicly available anonymous data, the institutional review board of
Brigham and Women’s Hospital granted exemption from review.
The primary aims of the study were to describe temporal trends in the
incidence of TAS and AVR (surgical repair/replacement or endovascular
repair) among patients with BAV. We collated patients hospitalized with
an International Classification of Diseases 9th Revision code of BAV
(746.4) undergoing concomitant AVR (35.10 or 35.11); AVR
(mechanical ¼ 35.22 or tissue ¼ 35.21) or resection of the thoracic vessel
with replacement (38.45); resection of vessel with anastomosis, aorta
(38.34); or endovascular implantation of the graft in the thoracic aorta
(39.73).
Covariates included age, gender, number of comorbidities as described
by Elixhauser and colleagues,31 aortic dissection, subacute bacterial340 The Journal of Thoracic and Cardiovascular Surgendocarditis, diagnosis of TAA, number of comorbidities, year and type
of surgery, and concomitant coronary artery bypass surgery or mitral valve
repair. Inpatient hospital characteristics ascertained were hospital teaching
status, hospital region (Northeast, Midwest, South, and West), and primary
insurance for the admission. Hospitalizations were grouped into 2-year in-
crements (1998/1999, 2000/2001, 2002/2003, 2004/2005, 2006/2007, and
2008/2009).
Continuous and categorical variables are presented as mean standard
error of the mean and percent  standard error percent, respectively. Stan-
dard errors of the estimates are presented to show the variance of the esti-
mate when extrapolated from the representative Nationwide Inpatient
Sample to the whole US population. Linear regression and logistic regres-
sion were used to model continuous dependent variables (eg, total charges,
length of stay) and the odds for dichotomous outcomes (eg, TAS, death),
respectively. Statistical analyses were performed using SAS for Windows
9.3 (SAS Institute Inc, Cary, NC). All analyses used provided sample
weights and accounted for complex sample design and hospital
clustering.32,33RESULTS
Hospitalizations of 50,415  3671 patients with BAV
who underwent AVR or TAS were examined. Demographic
and clinical characteristics are detailed in Table 1.Aortic Valve and Thoracic Aortic Surgery
Between 1998 and 2009, 48,736  3555 patients with
BAV underwent AVR (50.3%  2.2% with a mechanical
prosthesis; 47.6%  1.9% with a tissue prosthesis),
whereas only 2.4%  0.5% underwent valve repair. Of
patients undergoing AVR, 22.6%  1.0% underwent con-
comitant TAS. During the same period, 1679 162 patients
underwent isolated TAS. An endovascular approach, possi-
bly suggestive of descending thoracic aortic intervention,
was applied in 0.4%  0.1% of cases.
During the study period, the overall number of surgeries
per 2-year epoch increased 3.3-fold, with the number of iso-
lated AVRs increasing 2.7-fold, the number of AVRs with
concomitant TAS increasing 7.3-fold, and the number of
isolated TAS increasing 4.5-fold (Figure 1 and Table 2).
The proportion of AVRs that included a concomitant tho-
racic aortic intervention increased from 12.8%  1.4% to
28.5%  1.6% over the study period (Figure 2). Among
those who underwent AVR, mechanical valves were im-
planted in 69.2%  3.2% of patients in 1998/1999, but
that number had decreased to just 37.8%  3.7% of pa-
tients in 2008/2009 (Table 2). The same trend also was
seen in the subset of patients who underwent AVR in con-
junction with TAS (76.1%  4.7% mechanical in 1998/
1999 to 41.0%  4.5% in 2008/2009, P<.0001). The fre-
quency of mitral valve repair also increased over the study
period, but the proportion of patients undergoing mitral re-
pair was lower (Table 2). In contrast, the proportion of pa-
tients with BAV who underwent concomitant coronary
artery bypass grafting remained unchanged over the study
period.ery c August 2013
TABLE 1. Descriptive statistics for patients with bicuspid aortic valve who were hospitalized in the United States between 1998 and 2009 for aortic
valve or thoracic aortic surgery
All AVR only AVR with TAS Isolated TAS
P value% SE % SE % SE % SE
No. (n), weighted 50,395 3670 37,696 2564 11,020 1122 1679 162
Age, y (mean, SEM) 54.1 0.3 54.7 0.3 53.1 0.4 47.1 0.9 <.0001
Age group (y)
18-30 6.1 0.4 6.3 0.4 4.3 0.4 12.9 2.2 <.0001
>30-40 10.6 0.4 10.1 0.4 11.6 0.7 16.2 2.1
>40-50 18.9 0.5 17.5 0.6 22.5 1 26.7 2.2
>50-65 39.3 0.5 39.1 0.6 40.9 1 32.6 2.3
>65 25.1 0.7 27 0.7 20.7 1.1 11.6 1.9
Gender (female) 27 0.5 28.2 0.6 21.9 1 31.3 2.4 <.0001
Aortic dissection 2.4 0.2 0.7 0.1 6.8 0.6 11.8 1.8 <.0001
SBE 3.5 0.2 4.2 0.3 1.5 0.3 0.5 0.4 <.0001
Coarctation 1.2 0.1 0.6 0.1 0.9 0.2 14.6 2.2 <.0001
CABG 21.7 0.6 22.3 0.5 20.6 1.8 14.2 1.6 .04
TAA 26.3 1.1 7.1 0.5 84.8 1.1 72.6 2.6 <.0001
Mechanical valve 50.3 2.2 50.4 2 50.2 3.2 .94
Comorbidities
0 39.8 1.4 38.8 1.3 42 2.3 47.7 2.7 <.0001
1 31.1 0.6 30.8 0.7 32 1.1 31.4 2.6
2 17.6 0.6 18 0.6 16.8 1.2 13.4 2.1
3 11.6 0.7 12.4 0.8 9.2 1 7.5 1.5
Turner syndrome 0.3 0.1 0.2 0.1 0.4 0.1 2.1 0.8 <.0001
Marfan syndrome 0.3 0.1 0.1 0.04 0.7 0.2 1.5 0.7 <.0001
Teaching hospital 74.4 2.4 72.7 2.4 79.1 2.9 80.7 3.7 .0002
Hospital region
Northeast 19 2.8 18.5 2.5 21.4 4.2 15.7 3 <.0001
Midwest 31.1 3.6 29 3.2 37.2 5.3 38 4.6
South 28.7 3.4 30.8 3.4 21.9 3.7 26 4.5
West 21.1 2.3 21.7 2.2 19.5 3.2 20.2 4.2
Private insurance 64.1 0.8 61.7 0.9 71 1.2 73.7 2.6 <.0001
Died 1.6 0.1 1.5 0.2 1.8 0.3 2.9 0.9 .07
There was an increase in the overall number of AVR and TAS performed in patients with BAV in the United States over time. This increase was most marked for patients
undergoing AVR and concomitant TAS. AVR,Aortic valve repair or replacement; TAS, thoracic aortic surgery; SE, standard error; SEM, standard error of the mean; SBE, subacute
bacterial endocarditis; CABG, coronary artery bypass grafting; TAA, thoracic aortic aneurysm.
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DThe increase in the proportion of AVR surgeries that in-
cluded TAS over the study period was independent of age
group, gender, and hospital teaching status (Figure 3, A-C,
respectively) but was mirrored by an increase in the
reported diagnosis of TAA, from 15.0%  1.8% of admis-
sions in 1989/1990 to 33.4%  1.6% by 2008/2009;
77.8%  1.3% of those with TAA underwent concomitant
TAS.
Among patients undergoing AVR, there was no differ-
ence in the frequency of TAS among those without and
those with coarctation (22.6%  1.0% vs
30.4%  6.2%, respectively, P ¼ .15), although patients
with coarctation were more likely to undergo isolated
TAS (14.6%  2.1% of isolated aortic surgery was
among patients with coarctation, compared with only
1.2%  0.1% of the overall population).
Aortic dissection accounted for a decreasing proportion
of surgical BAV admissions, from 4.0%  0.7% toThe Journal of Thoracic and Ca2.3%  0.3% over the study period (P for trend ¼ .003).
There was no change in the proportion of admissions asso-
ciated with subacute bacterial endocarditis (overall
3.5% 0.2%; P for trend¼ .16) or coarctation of the aorta
(overall 1.2%  0.1%; P for trend ¼ .09).
Excluding patients with coarctation, subacute bacterial
endocarditis, aortic dissection, Marfan syndrome, and
Turner syndrome from the analysis did not affect the ob-
served trends.
Mortality and Resource Use
There was no difference in unadjusted hospital mortality
between those who underwent AVR who had concomitant
aortic surgery and those who underwent isolated AVR
(odds ratio [OR], 1.22; 95% confidence interval [CI],
0.83-1.81). Adjustment for clinical covariates similarly
failed to find an association (OR, 1.02; 95% CI,
0.67-1.57). There was a trend toward decreasingrdiovascular Surgery c Volume 146, Number 2 341
FIGURE 1. The number of surgical procedures performed in patients with
BAV in the United States from 1998 to 2009, stratified by procedure type.
There was an increase in the overall number of AVR and TAS among pa-
tients with BAV in the United States over time. This increase was most
marked for patients undergoing AVR and concomitant TAS. AVR, Aortic
valve repair or replacement; TAS, thoracic aortic surgery; BAV, bicuspid
aortic valve.
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Din-hospital mortality over the study period from
2.5%  0.6% in 1998/1999 to 1.5%  0.2% in 2008/
2009 (Table 2 and Figure 4; P for trend .02; multivariable
OR per 2-year time period, 0.89; 95% CI, 0.81-0.99;
P¼ .03). Although those undergoing isolated aortic surgery
had higher unadjustedmortality than those undergoing AVR
alone (OR, 2.04; 95% CI, 1.11-3.76), this was entirely ac-
counted for by the higher frequency of patients with aortic
dissection in the group undergoing isolated aortic surgery
(adjusting for dissection OR, 1.07; 95% CI, 0.53-2.17).
There was no difference in the length of stay for patients
undergoing AVR whether they did or did not undergo con-
comitant TAS (median 5 [6-8] vs 5 [6-9] days, P¼ .97) even
when adjusted for clinical and hospital covariates and epoch
(P ¼ .39). However, unadjusted total hospital charges for
those undergoing AVR and TAS were higher than those un-
dergoing isolated AVR ($97,370 vs $81,589, respectively,
þ$15,780  $3608; P< .0001). Adjustment for patient
and hospital characteristics, year of surgery, presence of
aortic dissection, endocarditis, coarctation, and concomi-
tant coronary artery bypass grafting, as well as medical co-
morbidities, decreased the cost differential for concomitant
TAS to þ$5563  $3281 (P ¼ .03). Total hospital charges
per hospitalization increased approximately 80%, from
$71,861  $2577 to $129,089  $4621 from 1998/1999
to 2008/2009 (inflation-adjusted 2009 dollars). Estimated
national total charges for all BAVand aortic surgery hospi-
talizations over this 12-year period were $5.0 billion, in-
creasing from $119 million in 1998 ($156 million
inflation-adjusted 2009 dollars) to $1.18 billion in 2009.
DISCUSSION
These data demonstrate an increase in TAS in patients
with BAV. There has been a steady increase in the342 The Journal of Thoracic and Cardiovascular Surgproportion of patients with BAV undergoing AVR and con-
comitant surgery on the thoracic aorta. The proportion of
patients with a diagnosis of TAA has paralleled the increase
in TAS, suggesting a more liberal definition of aortic aneu-
rysm associated with BAV. Greater use of tomographic radi-
ology (eg, computed tomography or magnetic resonance
imaging/angiography) and other imaging technologies
may have contributed to this trend. A greater number of pa-
tients undergoing surgery for a primary indication of tho-
racic aortic disease with AVR performed for otherwise
borderline aortic valve disease also may have a role. Given
the smaller number of patients undergoing aortic surgery
alone in the absence of dissection or coarctation, we suspect
this represents a minority of the additional TAS. These find-
ings do not simply reflect a universal trend of increasing use
of cardiac procedures. For example, the population fre-
quency of coronary bypass grafting surgery decreased be-
tween 2001/2002 and 2007/2008, whereas the use of
percutaneous coronary intervention remained stable.34
The annual number of AVR operations performed in the
United States increased modestly, only 28%, between
1998 and 2005.29
Professional society guidelines, such as those from the
American College of Cardiology (ACC) and American
Heart Association (AHA), have progressively recommen-
ded a more liberal approach to thoracic aortic dilation in pa-
tients with BAV, similar to the approach suggested for
patients with connective tissue disease. These recommen-
dations are mainly based on expert consensus in the ab-
sence of more definitive outcomes data. The 1998 ACC/
AHA guidelines for the management of valvular heart dis-
ease suggested that aortic root replacement was generally
indicated when the aortic diameter was 5 cm or more in
the setting of aortic regurgitation compelling AVR. No spe-
cific note was made of any considerations for BAV dis-
ease.21 The 2006 ACC/AHA guidelines for valvular heart
disease specifically discuss BAV with dilated ascending
aorta, noting a threshold for isolated intervention on an as-
cending aorta 5 cm or more in diameter, but lowering the
bar for patients undergoing AVR for severe aortic stenosis
or regurgitation to a threshold diameter of 4.5 cm.35 The
subsequent 2010 ACC/AHA guidelines on thoracic aortic
disease recommend that elective aortic intervention is indi-
cated for an aortic diameter of 4 to 5 cm for BAV (or any
other genetically mediated aortic disorder), independent
of aortic valve function.23 Some have suggested even lower
thresholds.24 There is considerable controversy regarding
these recommendations, and some investigators have
pointed to a lack of direct evidence that BAVaortic disease
is truly comparable to other genetic syndromes associated
with thoracic aortic disease, such as Marfan syn-
drome.9,26,36 In any case, the timing of the shift in aortic
surgery observed in the current report, occurring well
before official changes in guideline documents, suggestsery c August 2013
TABLE 2. Descriptive statistics for patients with bicuspid aortic valve hospitalized in the United States for aortic valve or thoracic aortic surgery
stratified by 2-year epoch between 1998 and 2009
1998/1999 2000/2001 2002/2003 2004/2005 2006/2007 2008/2009
P value%* SE % SE % SE % SE % SE % SE
No. (n), weighted 4556 571 5922 737 6464 635 8208 891 10,305 1095 14,960 2107 <.0001
Age, y (mean, SEM) 51.1 0.7 52.1 0.6 52.8 0.5 53.4 0.5 55.4 0.4 55.7 0.4 <.0001
Age group, y
18-30 10.0 1.2 8.3 0.9 5.5 0.6 6.7 0.8 4.0 0.5 5.4 0.5 <.0001
>30-40 12.7 1.4 11.4 1.1 16.0 1.2 9.5 0.8 10.2 0.8 8.3 0.5
>40-50 23.2 1.4 22.2 1.2 20.3 1.2 20.7 1.0 17.8 1.0 15.4 0.8
>50-65 32.6 1.5 36.0 1.5 34.1 1.3 41.1 1.1 41.2 1.1 42.4 0.9
>65 21.5 1.6 22.1 1.6 24.1 1.2 21.9 1.3 26.8 1.1 28.5 1.2
Gender (% female) 26.3 1.6 27.5 1.2 29.6 1.3 26.1 1.1 26.5 1.0 26.6 0.8 .42
Aortic dissection 4.0 0.7 3.3 0.5 2.5 0.5 1.7 0.3 1.9 0.4 2.3 0.3 .003
SBE 4.0 0.6 4.5 0.7 3.8 0.5 3.7 0.5 3.2 0.4 2.9 0.4 .009
Coarctation 1.2 0.4 1.5 0.3 0.5 0.2 1.5 0.3 1.4 0.2 1.0 0.2 .66
Comorbidities
0 44.2 2.1 40.9 1.7 34.5 1.5 28.5 1.5 22.0 1.1 15.5 1.5 <.0001
1 36.1 1.8 34.8 1.3 34.6 1.2 38.5 1.2 33.1 1.1 30.4 1.3
2 13.2 1.1 17.7 1.2 20.3 1.0 20.1 1.0 26.0 1.0 26.6 1.1
3 6.4 1.2 6.7 1.2 10.6 1.4 12.9 1.3 18.9 1.6 27.4 2.1
Mechanical valve 69.2 3.2 63.3 2.5 60.2 2.0 57.2 2.4 46.1 2.7 37.8 3.7 <.0001
Type of surgery
AVR only 85.0 1.6 83.2 1.7 79.4 1.8 73.6 2.0 71.8 1.7 69.0 1.5 <.0001
AVR with TAS 12.4 1.4 13.9 1.6 17.3 1.4 22.8 1.8 24.6 1.6 27.5 1.5
Isolated TAS 2.5 0.6 2.8 0.5 3.3 0.6 3.6 0.5 3.5 0.5 3.5 0.4
CABG 22.3 1.8 21.5 1.3 21.3 1.3 19.3 1.3 22.1 1.3 22.8 0.8 .43
Mitral valve repair 0.5 0.3 1.3 0.3 1.0 0.3 2.4 0.4 1.8 0.3 2.0 0.4 .004
TAA 15.0 1.8 16.3 1.6 22.2 1.6 27.0 1.7 28.6 1.5 33.4 1.6 <.0001
Teaching hospital 80.7 4.0 78.0 3.8 71.8 4.1 74.9 3.8 69.1 4.2 75.5 4.1 .33
Hospital region
Northeast 21.8 4.9 19.8 4.4 14.1 2.9 20.6 5.6 20.2 5.2 18.4 4.1 .30
Midwest 29.7 5.7 24.5 4.8 25.6 4.1 30.6 4.9 26.5 4.4 39.9 8.0
South 28.2 6.1 37.1 6.7 32.3 4.8 26.8 4.2 31.7 4.8 23.1 4.3
West 20.3 4.6 18.6 4.0 28.0 4.4 22.0 4.0 21.5 4.0 18.6 3.5
Private insurance 67.6 2.4 68.1 1.6 64.9 1.6 66.6 1.5 62.9 1.4 60.1 1.2 <.0001
Died 2.5 0.6 2.0 0.4 1.7 0.4 1.3 0.3 1.3 0.3 1.5 0.2 .02
SE, Standard error; SEM, standard error of the mean; SBE, subacute bacterial endocarditis; AVR, aortic valve replacement or repair; TAS, thoracic aortic surgery; CABG, coronary
artery bypass grafting; TAA, thoracic aortic aneurysm. *Data are presented as% with standard error% unless otherwise specified.
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practice in this instance.
We also observed an increase in the number of isolated
AVR for patients with a diagnosis of BAV. We think it un-
likely that this represents a true increase in aortic valve dis-
ease in patients with BAV, but rather a combination of
factors including improved diagnosis of BAV related to im-
aging technology and morewidespread awareness that BAV
is a common cause of aortic valve stenosis and regurgitation
in adults.
Improved surgical techniques and reduced morbidity and
mortality over the last 2 decades may have decreased pa-
tient or provider reluctance to proceed with surgery.37-39
It is notable that in-hospital mortality for patients undergo-
ing AVR alone was similar to AVR and concomitant TAS in
our population. This occurred despite the longer myocardial
ischemic and cardiopulmonary bypass time (and sometimesThe Journal of Thoracic and Cacirculatory arrest) associated with the addition of aortic
surgery.40,41 Although our observations may reflect
unmeasured differences in patient characteristics,
adjustments for available potential cofounders did not
alter this finding. Although counterintuitive, our results
mirror a prior single-center report that applied extensive
propensity score adjustments using more detailed clinical
data and also found no difference for in-hospital mortality.41
Our data cannot provide insight on more subtle functional
effects or postdischarge outcomes, which also are clearly
important for consideration of the risks and benefits of aor-
tic intervention.
The present data do not support a value judgment on the
trends described. Rather, the results highlight the impor-
tance of obtaining definitive data to guide clinicians in the
complex risk/benefit considerations involved. First, the
number of patients affected by these decisions is increasingrdiovascular Surgery c Volume 146, Number 2 343
FIGURE 2. Temporal trend in the proportion of hospitalizations in
which patients with BAV receiving AVR underwent concomitant TAS
(%  standard error %), 1998-2009. The increase in aortic surgery
was closely paralleled by an increase in diagnosis of TAA (dotted line).
SE, Standard error.
FIGURE 4. In-hospital mortality, by 2-year time period, for patients un-
dergoing isolated AVR and patients undergoing concomitant TAS. There
was a trend toward lower mortality over time for all groups. Data for iso-
lated TAS are not shown because of the smaller number of cases/deaths,
as well as distinct patient characteristics (ie, higher dissection and coarcta-
tion frequency). Error bars represent standard error%. AVR, Aortic valve
replacement or repair; TAS, thoracic aortic surgery.
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Ddramatically. Second, clinicians seem to be making major
changes in their approach to these issues based on indirect
evidence along with shifting expert consensus. Finally,FIGURE 3. Subgroup analysis of the proportion of patients undergoing AVR th
50 years or 50 or more years. A greater proportion of younger patients underwen
Men more frequently underwent aortic surgery, at an increasing frequency of th
formedmore frequently at teaching hospitals, at an increasing frequency of the st
concomitant aortic surgery over the study duration. There seemed to be a more
teaching hospitals.
344 The Journal of Thoracic and Cardiovascular Surgthese interventions constitute an increasing financial bur-
den. Taken together, these findings make a strong argument
that the growing population at risk and important ramifica-
tions of the clinical question merit collection of more rigor-
ous outcomes data on potential approaches toward TAS in
these patients.at included concomitant TAS for each time epoch. A, Patients aged less than
t aortic surgery, at an increasing frequency of the study duration. B, Gender.
e study duration. C, Type of hospital. Concomitant aortic surgery was per-
udy duration. Nonteaching hospitals did not show a similar trend to perform
consistent and prominent trend to a greater proportion of aortic surgeries in
ery c August 2013




Our findings must be interpreted in light of methodolog-
ical constraints. Large administrative databases have advan-
tages in terms of sample size and inclusiveness, but also
pose limitations on the analysis. International Classification
of Diseases 9th Revision codes provide limited clinical de-
tail, and the validity is unknown for most diagnoses studied.
There were no data on aortic size or other detailed clinical
data beyond diagnostic and procedural codes. However,
the population studied and clinical management are similar
to those reported in the literature for patients with BAVun-
dergoing AVR.41 We did not account for changes in the size
of the general population, but these changes are smaller than
those described (11% increase in the US adult population
from 2000 to 2009). In any case, such shifts would only af-
fect the absolute number of procedures and not the relative
proportions of patients managed with a given surgical strat-
egy. There is no mechanism linking multiple admissions for
a specific patient, although this should not pose a challenge
to the validity of the main finding of the study: a shift in ap-
proach to the thoracic aorta in this population. Although
general trends and correlates of such changes in manage-
ment can be described, the available data do not permit ex-
tensive analysis of the underlying causes. Data on hospital
charges reflect only inpatient charges and cannot be directly
translated to actual costs and exclude any associated outpa-
tient costs related to the diagnoses and procedures studied.
CONCLUSIONS
The annual number of AVR and TAS performed in pa-
tients with BAV increased between 1998 and 2009. Al-
though the number of isolated AVRs has grown, the most
dramatic shift has been in the application of TAS. These
findings likely reflect a greater sensitivity to aortic disease
in this population. Optimal management of bicuspid aortop-
athy remains undefined, however, and there is a pressing
need for rigorous investigation on the clinical approach to
the aorta in patients with BAV.
The authors thank Lilamarie Moko for help in preparing and re-
viewing the manuscript, and Gabriele Egidy Assenza for insightful
review of the manuscript.
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